Literature DB >> 3103152

The negative symptoms of schizophrenia and the monoamine oxidase inhibitors.

L Bucci.   

Abstract

Thirty chronic ambulatory schizophrenic patients whose main psychopathology was characterized by the persistence of negative symptoms, such as emotional withdrawal, depressed mood, motor retardation and blunted affect were included in this project in order to evaluate the therapeutic efficacy of tranylcypromine plus chlorpromazine therapy. The results show that tranylcypromine when added to the usual dose of chlorpromazine, in many instances, induces a definite improvement in these patients' clinical condition, that such treatment is safe and it may be also useful in preventing the occurrence of extra-pyramidal symptoms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3103152     DOI: 10.1007/bf00690936

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

1.  EFFECT OF MONOAMINE-OXIDASE INHIBITORS ON THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE IN THE HUMAN BRAIN.

Authors:  R MACLEAN; W J NICHOLSON; C M PARE; R S STACEY
Journal:  Lancet       Date:  1965-07-31       Impact factor: 79.321

2.  Drug therapy.

Authors:  J O COLE; R T JONES; G L KLERMAN
Journal:  Prog Neurol Psychiatry       Date:  1961

3.  The general practitioner and the schizophrenic patient.

Authors:  C M PARKES; G W BROWN; E M MONCK
Journal:  Br Med J       Date:  1962-04-07

4.  "Akinetic depression" in schizophrenia.

Authors:  T Van Putten; R P May
Journal:  Arch Gen Psychiatry       Date:  1978-09

5.  The dyskenesias: a new therapeutic approach.

Authors:  L Bucci
Journal:  Dis Nerv Syst       Date:  1971-05

6.  The mono-amine oxidase inhibitors; their usefulness and their safety.

Authors:  L Bucci
Journal:  Dis Nerv Syst       Date:  1969-12

Review 7.  Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs.

Authors:  R J Baldessarini; D Tarsy
Journal:  Annu Rev Neurosci       Date:  1980       Impact factor: 12.449

Review 8.  Molecular pathology of schizophrenia: more than one disease process?

Authors:  T J Crow
Journal:  Br Med J       Date:  1980-01-12

9.  Dopamine-sensitive adenylyl cyclase in human caudate nucleus. A study in control subjects and schizophrenic patients.

Authors:  A Carenzi; J C Gillin; A Guidotti; M A Schwartz; M Trabucchi; R J Wyatt
Journal:  Arch Gen Psychiatry       Date:  1975-08

10.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06
View more
  6 in total

Review 1.  Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison.

Authors:  S R Kay
Journal:  Psychiatr Q       Date:  1990

2.  Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys.

Authors:  R Heintz; D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 3.  Histone modifications, DNA methylation, and schizophrenia.

Authors:  David P Gavin; Rajiv P Sharma
Journal:  Neurosci Biobehav Rev       Date:  2009-10-30       Impact factor: 8.989

Review 4.  [Treatment of cognitive deficits in schizophrenia. Part 2: Pharmacological strategies].

Authors:  D Roesch-Ely; U Pfueller; C Mundt; U Müller; M Weisbrod
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

Review 5.  Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia.

Authors:  H J Möller; H M van Praag; B Aufdembrinke; P Bailey; T R Barnes; J Beck; H Bentsen; F X Eich; L Farrow; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

6.  Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia.

Authors:  Ivan D Montoya; Frank Vocci
Journal:  J Dual Diagn       Date:  2007-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.